Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement 21 January
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial 18 December 2025
